Venetoclax blood levels and side effects in AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial checks how the amount of venetoclax in your blood relates to side effects after you are in remission from AML. It aims to help doctors find the safest dose for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML).
- You are in remission (the leukemia is not active) after your first round of maintenance treatment.
- You received treatment with a hypomethylating agent (like azacitidine or decitabine) plus venetoclax.
- You are not taking medicines that strongly affect how venetoclax works (like certain antifungal or seizure drugs).
- You are willing to have your venetoclax blood levels checked regularly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how blood levels of the drug venetoclax relate to remission in adults with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. It aims to help doctors dose the drug more effectively.
This trial tests whether taking venetoclax can help keep your leukemia from coming back after you reach complete remission. It is for patients who are not able to get a bone marrow transplant right away.
This study looks at how the drug venetoclax works in people newly diagnosed with acute myeloid leukemia (AML). It helps doctors understand the right dose for better results.
This Phase 1 trial studies whether a combination of venetoclax (ABT-199) and “purine analogues” can help adults with AML that has come back or didn’t respond to earlier treatment. It’s designed to test safety and early effectiveness in people who haven’t previously developed resistance to venetoclax.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.